drugset / Trial / NCT06940401
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Phase 1/2
Active not recruiting
44 enrolled
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, and preliminary efficacy of JS111 capsules in patients with locally advanced, metastatic, or recurrent NSCLC harboring EGFR mutations;to determine the recommended Phase II dose (RP2D).
Timeline
- Start
- 2025-04-30
- Primary completion
- 2028-07-30
- Completion
- 2028-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS111 | Unknown | 160 mg | Oral |
| Subject | JS111 | Unknown | 240 mg | Oral |